Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Acusphere completes Phase I trial of heart agent:

This article was originally published in Clinica

Executive Summary

Start-up drug delivery company Acusphere has completed Phase I clinical trials of its third-generation ultrasound agent for assessing myocardial perfusion in heart disease patients. The Cambridge, Massachusetts-based company's AI-700 agent is the first application of its porous microparticle technology, which is also being applied to drug delivery. The ultrasound agent is intended to withstand the impact of the ultrasound beam and therefore allow a longer imaging duration.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT079073

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel